{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:29:11Z","timestamp":1789010951437,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00415-024-12797-0","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T12:55:25Z","timestamp":1736945725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Unraveling the inflammation\u2013degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer"],"prefix":"10.1007","volume":"272","author":[{"given":"Aurora","family":"Zangh\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermete","family":"Giancipoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-9057","authenticated-orcid":false,"given":"Emanuele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"3","key":"12797_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/WCO.0000000000001262","volume":"37","author":"S Krieger","year":"2024","unstructured":"Krieger S, Cook K, Hersh CM (2024) Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold. Curr Opin Neurol 37(3):189\u2013201","journal-title":"Curr Opin Neurol"},{"key":"12797_CR2","unstructured":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024; 23(4): 344\u201381."},{"issue":"1","key":"12797_CR3","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1038\/s41467-024-48602-9","volume":"15","author":"T Chitnis","year":"2024","unstructured":"Chitnis T, Qureshi F, Gehman VM, Becich M, Bove R, Cree BAC et al (2024) Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis. Nat Commun 15(1):4297","journal-title":"Nat Commun"},{"issue":"11","key":"12797_CR4","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.3390\/ijms23115877","volume":"23","author":"J Yang","year":"2022","unstructured":"Yang J, Hamade M, Wu Q, Wang Q, Axtell R, Giri S et al (2022) Current and future biomarkers in multiple sclerosis. Int J Mol Sci 23(11):5877","journal-title":"Int J Mol Sci"},{"key":"12797_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jns.2016.12.039","volume":"373","author":"KPZ Ferreira","year":"2017","unstructured":"Ferreira KPZ, Oliveira SR, Kallaur AP, Kaimen-Maciel DR, Lozovoy MAB, de Almeida ERD et al (2017) Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis. J Neurol Sci 373:236\u2013241","journal-title":"J Neurol Sci"},{"key":"12797_CR6","doi-asserted-by":"publisher","first-page":"1376838","DOI":"10.3389\/fimmu.2024.1376838","volume":"15","author":"C Tang","year":"2024","unstructured":"Tang C, Yang J, Zhu C, Ding Y, Yang S, Xu B et al (2024) Iron metabolism disorder and multiple sclerosis: a comprehensive analysis. Front Immunol 15:1376838","journal-title":"Front Immunol"},{"issue":"12","key":"12797_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrneurol.2015.222","volume":"11","author":"G Mandolesi","year":"2015","unstructured":"Mandolesi G, Gentile A, Musella A, Fresegna D, De Vito F, Bullitta S et al (2015) Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat Rev Neurol 11(12):711\u2013724","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"12797_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, H\u00f6glund K, Cullen NC, Kvartsberg H, Andreasson U et al (2018) Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol 136(3):363\u2013376","journal-title":"Acta Neuropathol"},{"key":"12797_CR9","doi-asserted-by":"publisher","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","volume":"101","author":"MS Freedman","year":"2024","unstructured":"Freedman MS, Gnanapavan S, Booth RA, Calabresi PA, Khalil M, Kuhle J et al (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine 101:104970","journal-title":"EBioMedicine"},{"key":"12797_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nbd.2015.02.007","volume":"81","author":"S Levi","year":"2015","unstructured":"Levi S, Rovida E (2015) Neuroferritinopathy: from ferritin structure modification to pathogenetic mechanism. Neurobiol Dis 81:134\u2013143","journal-title":"Neurobiol Dis"},{"issue":"3","key":"12797_CR11","doi-asserted-by":"publisher","first-page":"e24786","DOI":"10.1016\/j.heliyon.2024.e24786","volume":"10","author":"S Mohan","year":"2024","unstructured":"Mohan S, Alhazmi HA, Hassani R, Khuwaja G, Maheshkumar VP, Aldahish A et al (2024) Role of ferroptosis pathways in neuroinflammation and neurological disorders: from pathogenesis to treatment. Heliyon 10(3):e24786","journal-title":"Heliyon"},{"issue":"10","key":"12797_CR12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3390\/ijms17101725","volume":"17","author":"E D'Amico","year":"2016","unstructured":"D\u2019Amico E, Patti F, Zangh\u00ec A, Zappia M (2016) A personalized approach in progressive multiple sclerosis: the current status of disease modifying therapies (DMTs) and future perspectives. Int J Mol Sci 17(10):1725","journal-title":"Int J Mol Sci"},{"key":"12797_CR13","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1038\/ncomms7760","volume":"6","author":"S Ayton","year":"2015","unstructured":"Ayton S, Faux NG, Bush AI (2015) Ferritin levels in the cerebrospinal fluid predict Alzheimer\u2019s disease outcomes and are regulated by APOE. Nat Commun 6:6760","journal-title":"Nat Commun"},{"issue":"3","key":"12797_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/jnnp-2022-330052","volume":"94","author":"S Ayton","year":"2023","unstructured":"Ayton S, Janelidze S, Kalinowski P, Palmqvist S, Belaidi AA, Stomrud E et al (2023) CSF ferritin in the clinicopathological progression of Alzheimer\u2019s disease and associations with APOE and inflammation biomarkers. J Neurol Neurosurg Psychiatry 94(3):211","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"19","key":"12797_CR15","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.3390\/jcm10194575","volume":"10","author":"M Dulewicz","year":"2021","unstructured":"Dulewicz M, Kulczy\u0144ska-Przybik A, S\u0142owik A, Borawska R, Mroczko B (2021) Neurogranin and neuronal pentraxin receptor as synaptic dysfunction biomarkers in Alzheimer\u2019s disease. J Clin Med 10(19):4575","journal-title":"J Clin Med"},{"key":"12797_CR16","doi-asserted-by":"publisher","first-page":"584743","DOI":"10.3389\/fnagi.2020.584743","volume":"12","author":"Y Xiang","year":"2020","unstructured":"Xiang Y, Xin J, Le W, Yang Y (2020) Neurogranin: a potential biomarker of neurological and mental diseases. Front Aging Neurosci 12:584743","journal-title":"Front Aging Neurosci"},{"key":"12797_CR17","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3389\/fimmu.2019.01668","volume":"10","author":"P Gervois","year":"2019","unstructured":"Gervois P, Lambrichts I (2019) The emerging role of triggering receptor expressed on myeloid cells 2 as a target for immunomodulation in ischemic stroke. Front Immunol 10:1668","journal-title":"Front Immunol"},{"key":"12797_CR18","doi-asserted-by":"publisher","first-page":"115218","DOI":"10.1016\/j.biopha.2023.115218","volume":"165","author":"Y Li","year":"2023","unstructured":"Li Y, Xu H, Wang H, Yang K, Luan J, Wang S (2023) TREM2: potential therapeutic targeting of microglia for Alzheimer\u2019s disease. Biomed Pharmacother 165:115218","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"12797_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13024-022-00588-y","volume":"17","author":"J Hou","year":"2022","unstructured":"Hou J, Chen Y, Grajales-Reyes G, Colonna M (2022) TREM2 dependent and independent functions of microglia in Alzheimer\u2019s disease. Mol Neurodegener 17(1):84","journal-title":"Mol Neurodegener"},{"issue":"29","key":"12797_CR20","doi-asserted-by":"publisher","first-page":"2347232024","DOI":"10.1523\/JNEUROSCI.2347-23.2024","volume":"44","author":"A Etxeberria","year":"2024","unstructured":"Etxeberria A, Shen YAA, Vito S, Silverman SM, Imperio J, Lalehzadeh G et al (2024) Neutral or detrimental effects of TREM2 agonist antibodies in preclinical models of Alzheimer\u2019s disease and multiple sclerosis. J Neurosci 44(29):2347232024","journal-title":"J Neurosci"},{"issue":"3","key":"12797_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21037\/aes.2018.05.08","volume":"2018","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Costello F (2018) The role of optical coherence tomography in neuro-ophthalmology. Annal Eye Sci 2018(3):35","journal-title":"Annal Eye Sci"},{"issue":"3","key":"12797_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/aos.15722","volume":"102","author":"A Montol\u00edo","year":"2024","unstructured":"Montol\u00edo A, Cego\u00f1ino J, Garcia-Martin E, P\u00e9rezdelPalomar A (2024) The macular retinal ganglion cell layer as a biomarker for diagnosis and prognosis in multiple sclerosis: a deep learning approach. Acta Ophthalmol 102(3):272\u2013284","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"12797_CR23","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1111\/aos.15722","volume":"102","author":"A Montol\u00edo","year":"2024","unstructured":"Montol\u00edo A, Cego\u00f1ino J, Garcia-Martin E, P\u00e9rez Del Palomar A (2024) The macular retinal ganglion cell layer as a biomarker for diagnosis and prognosis in multiple sclerosis: a deep learning approach. Acta Ophthalmol 102(3):e272\u2013e284","journal-title":"Acta Ophthalmol"},{"key":"12797_CR24","doi-asserted-by":"publisher","first-page":"128517","DOI":"10.1155\/2014\/128517","volume":"2014","author":"JJ Gonz\u00e1lez-L\u00f3pez","year":"2014","unstructured":"Gonz\u00e1lez-L\u00f3pez JJ, Rebolleda G, Leal M, Oblanca N, Mu\u00f1oz-Negrete FJ, Costa-Frossard L et al (2014) Comparative diagnostic accuracy of ganglion cell-inner plexiform and retinal nerve fiber layer thickness measures by Cirrus and Spectralis optical coherence tomography in relapsing-remitting multiple sclerosis. Biomed Res Int 2014:128517","journal-title":"Biomed Res Int"},{"issue":"2","key":"12797_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"13","key":"12797_CR26","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1177\/1352458513488232","volume":"19","author":"C Teunissen","year":"2013","unstructured":"Teunissen C, Menge T, Altintas A, \u00c1lvarez-Cerme\u00f1o JC, Bertolotto A, Berven FS et al (2013) Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 19(13):1802\u20131809","journal-title":"Mult Scler"},{"issue":"9","key":"12797_CR27","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S1474-4422(10)70168-X","volume":"9","author":"A Petzold","year":"2010","unstructured":"Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A et al (2010) Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 9(9):921\u2013932","journal-title":"Lancet Neurol"},{"issue":"10","key":"12797_CR28","doi-asserted-by":"publisher","first-page":"e2302","DOI":"10.1002\/brb3.2302","volume":"11","author":"A Mehmood","year":"2021","unstructured":"Mehmood A, Ali W, Song S, Din ZU, Guo RY, Shah W et al (2021) Optical coherence tomography monitoring and diagnosing retinal changes in multiple sclerosis. Brain Behav 11(10):e2302","journal-title":"Brain Behav"},{"key":"12797_CR29","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3389\/fimmu.2020.01799","volume":"11","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Cai MT, Yang F, Zhou JP, Fang W, Shen CH et al (2020) IgG index revisited: diagnostic utility and prognostic value in multiple sclerosis. Front Immunol 11:1799","journal-title":"Front Immunol"},{"issue":"8","key":"12797_CR30","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/ijms23084287","volume":"23","author":"C Corral-Domenge","year":"2022","unstructured":"Corral-Domenge C, de la Villa P, Mansilla A, Germain F (2022) Tools and biomarkers for the study of retinal ganglion cell degeneration. Int J Mol Sci 23(8):4287","journal-title":"Int J Mol Sci"},{"key":"12797_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fnagi.2013.00024","volume":"5","author":"D Song","year":"2013","unstructured":"Song D, Dunaief JL (2013) Retinal iron homeostasis in health and disease. Front Aging Neurosci 5:24","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"12797_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1471-4159.2011.07536.x","volume":"120","author":"R Williams","year":"2012","unstructured":"Williams R, Buchheit CL, Berman NE, LeVine SM (2012) Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem 120(1):7\u201325","journal-title":"J Neurochem"},{"issue":"4","key":"12797_CR33","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41380-023-02399-z","volume":"29","author":"S Levi","year":"2024","unstructured":"Levi S, Ripamonti M, Moro AS, Cozzi A (2024) Iron imbalance in neurodegeneration. Mol Psychiatry 29(4):1139\u20131152","journal-title":"Mol Psychiatry"},{"issue":"13","key":"12797_CR34","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.3390\/ijms23137267","volume":"23","author":"RJ Ward","year":"2022","unstructured":"Ward RJ, Dexter DT, Crichton RR (2022) Iron, neuroinflammation and neurodegeneration. Int J Mol Sci 23(13):7267","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12797_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S (2023) Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther 8(1):359","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl 2","key":"12797_CR36","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1007\/s10072-010-0438-7","volume":"31","author":"F Patti","year":"2010","unstructured":"Patti F, Leone C, D\u2019Amico E (2010) Treatment options of cognitive impairment in multiple sclerosis. Neurol Sci 31(Suppl 2):S265\u2013S269","journal-title":"Neurol Sci"},{"key":"12797_CR37","doi-asserted-by":"publisher","first-page":"102950","DOI":"10.1016\/j.msard.2021.102950","volume":"51","author":"J Sandry","year":"2021","unstructured":"Sandry J, Simonet DV, Brandstadter R, Krieger S, Katz Sand I, Graney RA et al (2021) The Symbol Digit Modalities Test (SDMT) is sensitive but non-specific in MS: Lexical access speed, memory, and information processing speed independently contribute to SDMT performance. Multiple Sclerosis Relat Disord 51:102950","journal-title":"Multiple Sclerosis Relat Disord"},{"issue":"13","key":"12797_CR38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1177\/1352458518808204","volume":"25","author":"L Strober","year":"2019","unstructured":"Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N et al (2019) Symbol digit modalities test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis. Multiple Scleros (Houndmills, Basingstoke, England) 25(13):1781\u20131790","journal-title":"Multiple Scleros (Houndmills, Basingstoke, England)"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12797-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:40:23Z","timestamp":1739637623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12797-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["12797"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12797-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aurora Zangh\u00ec has nothing to disclose related to the submitted manuscript. Annamaria Greco has nothing to disclose related to the submitted manuscript. Ermete Giancipoli has nothing to disclose related to the submitted manuscript. Hayrettin Tumani has nothing to disclose related to the submitted manuscript. Carlo Avolio has nothing to disclose related to the submitted manuscript. Emanuele D\u2019Amico has nothing to disclose related to the submitted manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the local ethics committee (Comitato Etico Foggia, CE\/109\/2024\/PO). All patients signed a written informed consent to participate in the study. The current report does not contain any individual or identifying information. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research ethics and patient consent"}}],"article-number":"109"}}